Valuation: Tsubota Laboratory Incorporated

Market Cap 709.34Cr 4.45Cr 3.84Cr 3.61Cr 3.28Cr 6.17Cr 425.64Cr 6.26Cr 42Cr 17Cr 213.24Cr 17Cr 16Cr P/E 2025
49.7x
P/E 2026 -9.95x
Enterprise Value 619.24Cr 3.89Cr 3.35Cr 3.15Cr 2.87Cr 5.39Cr 371.57Cr 5.47Cr 37Cr 14Cr 186.16Cr 15Cr 14Cr EV / Sales 2025
6.38x
EV / Sales 2026 33.4x
Free-Float
28.38%
Yield 2025 *
-
Yield 2026 -
17/06 Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
01/06 Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
01/06 Tsubota Laboratory Incorporated signed a letter of intent to acquire MediProduce, Inc. from Eri Kubota for ¥150 million. CI
15/05 Tsubota Laboratory Incorporated Reports Earnings Results for the Full Year Ended March 31, 2026 CI
15/05 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
13/02 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
13/02 Tsubota Laboratory Incorporated Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
12/25/12 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
17/25/17 Tsubota Laboratory Incorporated Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
20/24/20 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
19/22/19 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022. CI
20/22/20 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022. CI
23/22/23 Tsubota Laboratory Incorporated has completed an IPO in the amount of Ñ1.8048 billion. CI
1 day-0.72%
1 week+5.77%
Current month+11.34%
1 month+16.03%
3 months+0.73%
6 months+3.38%
Current year-19.12%
1 week 267
Extreme 267
283
1 month 226
Extreme 226
288
Current year 210
Extreme 210
478
1 year 210
Extreme 210
478
3 years 210
Extreme 210
625
5 years 210
Extreme 210
1,447
10 years 210
Extreme 210
1,447
Manager TitleAgeSince
President 71 01/02/2019
Chief Administrative Officer - -
Chief Tech/Sci/R&D Officer 65 01/01/2025
Director TitleAgeSince
Director/Board Member 71 01/02/2019
Director/Board Member 70 01/06/2020
Director/Board Member 55 01/06/2023
Date Insider Type Main position Quantity % Market Cap.
15/11/24 Others

Founder

63,000 0.2465%
15/11/24 Others

Founder

4,20,000 1.6434%
Change 5-day change 1-year change 3-year change Capi.($)
-0.72%+5.77%-22.97%-43.42% 4.49Cr
+0.68%-2.28%+1.91%+19.70% 4.84TCr
+5.88%+3.99%+490.45%+634.79% 4.37TCr
+3.77%+0.39%+12.87%+87.44% 3.95TCr
+1.79%-0.70%+24.80%+12.17% 3.9TCr
-0.50%+0.85%+20.60%+58.18% 3.26TCr
-0.11%-3.11% - - 1.63TCr
+2.47%-1.75%+27.87%+133.41% 1.61TCr
-0.62%-0.06%+3.95%+27.74% 1.42TCr
+2.09%+3.09%+81.91%+42.87% 1.34TCr
Average +1.45%+0.34%+71.27%+108.10% 2.63TCr
Weighted average by Cap. +2.06%-0.62%+102.29%+152.37%

Financials

2025 2026
Net sales 135.7Cr 85.16L 73.52L 68.97L 62.82L 1.18Cr 81Cr 1.2Cr 8.09Cr 3.17Cr 41Cr 3.2Cr 3.13Cr 20Cr 12.55L 10.84L 10.17L 9L 17.41L 12Cr 17.65L 1.19Cr 46.7L 6.01Cr 47.12L 46.1L
Net income 20Cr 12.87L 11.11L 10.42L 9L 17.84L 12Cr 18.09L 1.22Cr 47.87L 6.16Cr 48.3L 47.26L -76Cr -47.76L -41.23L -38.68L -35.23L -66.24L -46Cr -67.16L -4.53Cr -1.78Cr -23Cr -1.79Cr -1.75Cr
Net Debt -144.8Cr -90.87L -78.45L -73.6L -67.03L -1.26Cr -87Cr -1.28Cr -8.63Cr -3.38Cr -44Cr -3.41Cr -3.34Cr -90Cr -56.54L -48.81L -45.8L -41.71L -78.43L -54Cr -79.52L -5.37Cr -2.1Cr -27Cr -2.12Cr -2.08Cr
Logo Tsubota Laboratory Incorporated
Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
Employees
-
Date Price Change Volume
17/26/17 JP¥275.00 -0.72% 50,800
14/26/14 JP¥277.00 +0.36% 26,300
13/26/13 JP¥276.00 +0.36% 63,000
12/26/12 JP¥275.00 +2.23% 48,500
10/26/10 JP¥269.00 +3.46% 37,000
  1. Stock Market
  2. Stocks
  3. 4890 Stock